The Identification of a Tumor Infiltration CD8+ T-Cell Gene Signature That Can Potentially Improve the Prognosis and Prediction of Immunization Responses in Papillary Renal Cell Carcinoma.

Abstract

BACKGROUND:

CD8+ T cells, vital effectors pertaining to adaptive immunity, display close relationships to the immunization responses to kill tumor cells. Understanding the effect exerted by tumor infiltration CD8+ T cells in papillary renal cell carcinoma (papRCC) is critical for assessing the prognosis process and responses to immunization therapy in cases with this disease.

MATERIALS AND APPROACHES:

The single-cell transcriptome data of papRCC were used for screening CD8+ T-cell-correlated differentially expressed genes to achieve the following investigations. On that basis, a prognosis gene signature associated with tumor infiltration CD8+ T cell was built and verified with The Cancer Genome Atlas data set. Risk scores were determined for papRCC cases and categorized as high- or low-risk groups. The prognosis significance for risk scores was assessed with multiple-variate Cox investigation and Kaplan-Meier survival curves. In addition, the possible capability exhibited by the genetic profiles of cases to assess the response to immunization therapy was further explored.

RESULTS:

Six hundred twenty-one cell death-inhibiting RNA genes were screened using single-cell RNA sequencing. A gene signature consisting of seven genes (LYAR, YBX1, PNRC1, TCF25, MYL12B, MINOS1, and LINC01420) was then identified, and this collective was considered to be an independent prognosis indicator that could strongly assess overall survival in papRCC. In addition, the data allowed papRCC cases to fall to cohorts at high and low risks, exhibiting a wide range of clinically related features as well as different CD8+ T-cell immunization infiltration and immunization therapy responses.

CONCLUSIONS:

Our work provides a possible explanation for the limited response of current immunization checkpoint-inhibiting elements for combating papRCC. Furthermore, the researchers built a novel genetic signature that was able to assess the prognosis and immunotherapeutic response of cases. This may also be considered as a promising therapeutic target for the disease.

• Authors: Jie Wang, Meiying Huang, Peng Huang, Jingjie Zhao, Junhua Tan, Feifan Huang, Ruiying Ma, Yu Xiao, Gao Deng, Liuzhi Wei, Qiuju Wei, Zechen Wang, Siyuan He, Jiajia Shen, Suren Sooranna, Lingzhang Meng, Jian Song
• Journal: Frontiers in oncology (Front Oncol) Vol. 11 Pg. 757641 ( 2021) ISSN: 2234-943X [Print] Switzerland
• PMID: 34858833 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Wang, Huang, Huang, Zhao, Tan, Huang, Ma, Xiao, Deng, Wei, Wei, Wang, He, Shen, Sooranna, Meng and Song.